BridgeBio Pharma reported Q4 2024 revenue of $5.9 million, a significant increase from the prior year period, primarily driven by the first commercial sales of Attruby in the U.S. The company faced a net loss of $265.1 million, attributed to increased SG&A expenses related to commercialization efforts. Operating costs surged due to higher marketing and sales expenses, while cash and cash equivalents reached $681 million. The company continues to progress its pipeline with multiple Phase 3 studies advancing towards completion.